• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

噬菌体溶菌素:一种新型抗感染药物,可控制革兰氏阳性病原体。

Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens.

机构信息

Laboratory of Bacterial Pathogenesis, Rockefeller University, 1230 York Avenue, New York, NY 10021, USA.

出版信息

Int J Med Microbiol. 2010 Aug;300(6):357-62. doi: 10.1016/j.ijmm.2010.04.002. Epub 2010 May 10.

DOI:10.1016/j.ijmm.2010.04.002
PMID:20452280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3666336/
Abstract

Endolysins (or lysins) are highly evolved enzymes produced by bacteriophage (phage for short) to digest the bacterial cell wall for phage progeny release. In Gram-positive bacteria, small quantities of purified recombinant lysin added externally results in immediate lysis causing log-fold death of the target bacterium. Lysins have been used successfully in a variety of animal models to control pathogenic antibiotic-resistant bacteria found on mucosal surfaces and infected tissues. Their specificity for the pathogen without disturbing the normal flora, the low chance of bacterial resistance, and their ability to kill colonizing pathogens on mucosal surfaces, a capacity previously unavailable, make them ideal anti-infectives in an age of mounting resistance. Here we review the current literature showing the effectiveness of these enzymes in controlling a variety of infections.

摘要

溶菌素(或裂解酶)是噬菌体产生的高度进化的酶,用于消化细菌细胞壁以释放噬菌体后代。在革兰氏阳性菌中,少量纯化的重组溶菌素添加到外部会立即导致细胞裂解,导致目标细菌对数级死亡。溶菌素已成功用于多种动物模型,以控制在粘膜表面和感染组织上发现的致病性抗生素耐药菌。它们对病原体的特异性而不干扰正常菌群,细菌耐药的可能性低,以及它们在粘膜表面杀死定植病原体的能力,这是以前无法实现的,使它们成为耐药时代的理想抗感染药物。在这里,我们回顾了目前的文献,这些文献表明这些酶在控制各种感染方面的有效性。

相似文献

1
Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens.噬菌体溶菌素:一种新型抗感染药物,可控制革兰氏阳性病原体。
Int J Med Microbiol. 2010 Aug;300(6):357-62. doi: 10.1016/j.ijmm.2010.04.002. Epub 2010 May 10.
2
Bacteriophage lysins as effective antibacterials.噬菌体裂解酶作为有效的抗菌剂。
Curr Opin Microbiol. 2008 Oct;11(5):393-400. doi: 10.1016/j.mib.2008.09.012. Epub 2008 Oct 14.
3
Bacteriophage lytic enzymes: novel anti-infectives.噬菌体裂解酶:新型抗感染药物。
Trends Microbiol. 2005 Oct;13(10):491-6. doi: 10.1016/j.tim.2005.08.007.
4
Exploiting what phage have evolved to control gram-positive pathogens.利用噬菌体进化而来的控制革兰氏阳性病原体的能力。
Bacteriophage. 2011 Jul 1;1(4):188-194. doi: 10.4161/bact.1.4.17747.
5
Lysin Therapy for Staphylococcus aureus and Other Bacterial Pathogens.溶菌治疗金黄色葡萄球菌和其他细菌病原体。
Curr Top Microbiol Immunol. 2017;409:529-540. doi: 10.1007/82_2015_5005.
6
Bacteriophages and bacteriophage-derived endolysins as potential therapeutics to combat Gram-positive spore forming bacteria.噬菌体和噬菌体衍生的溶菌酶作为对抗革兰氏阳性芽孢形成细菌的潜在疗法。
J Appl Microbiol. 2015 Sep;119(3):620-31. doi: 10.1111/jam.12881. Epub 2015 Aug 2.
7
Lysins: the arrival of pathogen-directed anti-infectives.溶菌素:靶向病原体的抗感染药物的问世。
J Med Microbiol. 2013 Oct;62(Pt 10):1506-1516. doi: 10.1099/jmm.0.061028-0. Epub 2013 Jun 27.
8
Recombinant bacteriophage lysins as antibacterials.重组噬菌体裂解酶作为抗菌剂。
Bioeng Bugs. 2010 Jan-Feb;1(1):9-16. doi: 10.4161/bbug.1.1.9818.
9
TSPphg Lysin from the Extremophilic Thermus Bacteriophage TSP4 as a Potential Antimicrobial Agent against Both Gram-Negative and Gram-Positive Pathogenic Bacteria.极端嗜热菌 TSP4 噬菌体 TSPphg 溶菌酶作为一种潜在的抗革兰氏阴性和革兰氏阳性病原菌的抗菌剂。
Viruses. 2020 Feb 9;12(2):192. doi: 10.3390/v12020192.
10
LysSAP26, a New Recombinant Phage Endolysin with a Broad Spectrum Antibacterial Activity.LysSAP26,一种具有广谱抗菌活性的新型重组噬菌体溶菌酶。
Viruses. 2020 Nov 23;12(11):1340. doi: 10.3390/v12111340.

引用本文的文献

1
Endolysin selectively kills Gardnerella ex vivo in vaginal samples from women with bacterial vaginosis.溶菌酶在体外可选择性杀死患有细菌性阴道病女性阴道样本中的加德纳菌。
NPJ Biofilms Microbiomes. 2025 Aug 12;11(1):161. doi: 10.1038/s41522-025-00764-0.
2
Use of the bacteriophage-derived endolysin CHAPK-SH3blys as a potent novel treatment for biofilm-associated wound infections.将噬菌体衍生的内溶素CHAPK-SH3blys用作治疗生物膜相关伤口感染的一种有效的新型疗法。
Microbiol Spectr. 2025 Sep 2;13(9):e0071625. doi: 10.1128/spectrum.00716-25. Epub 2025 Aug 5.
3
Whole genome sequence data of NIBL1955 isolated from rice.从水稻中分离出的 NIBL1955 的全基因组序列数据。
Data Brief. 2025 Jun 10;61:111771. doi: 10.1016/j.dib.2025.111771. eCollection 2025 Aug.
4
Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside.噬菌体和溶菌酶治疗耐药细菌:从实验室到临床应用
MedComm (2020). 2025 Jul 13;6(7):e70280. doi: 10.1002/mco2.70280. eCollection 2025 Jul.
5
Heterodimerization of staphylococcal phage φ2638A endolysin isoforms and their functional role in bacterial lysis.葡萄球菌噬菌体φ2638A内溶素亚型的异源二聚化及其在细菌裂解中的功能作用。
Microlife. 2025 Jun 10;6:uqaf011. doi: 10.1093/femsml/uqaf011. eCollection 2025.
6
Phage therapy for Klebsiella pneumoniae: Understanding bacteria-phage interactions for therapeutic innovations.肺炎克雷伯菌的噬菌体疗法:理解细菌与噬菌体的相互作用以实现治疗创新。
PLoS Pathog. 2025 Apr 8;21(4):e1012971. doi: 10.1371/journal.ppat.1012971. eCollection 2025 Apr.
7
Isolation, identification, and genome analysis of the novel Escherichia coli phage XH12 and enhancement of the antibacterial activity of its lysozyme by chimeric cationic peptides.新型大肠杆菌噬菌体XH12的分离、鉴定及基因组分析,以及嵌合阳离子肽增强其溶菌酶抗菌活性的研究
Arch Virol. 2025 Mar 27;170(5):91. doi: 10.1007/s00705-025-06274-w.
8
Alternative approaches to antibiotics in the control of mastitis in dairy cows: a review.奶牛乳腺炎防控中抗生素的替代方法:综述
Vet Res Commun. 2025 Mar 24;49(3):150. doi: 10.1007/s11259-025-10720-0.
9
Phage-derived proteins: Advancing food safety through biocontrol and detection of foodborne pathogens.噬菌体衍生蛋白:通过生物防治和食源性病原体检测推进食品安全。
Compr Rev Food Sci Food Saf. 2025 Mar;24(2):e70124. doi: 10.1111/1541-4337.70124.
10
Novel Anti-Microbial/Anti-Inflammatory Combination Improves Clinical Outcome of Bacillus cereus Endophthalmitis.新型抗菌/抗炎联合疗法改善蜡样芽孢杆菌性眼内炎的临床疗效。
Invest Ophthalmol Vis Sci. 2025 Jan 2;66(1):39. doi: 10.1167/iovs.66.1.39.

本文引用的文献

1
Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia.溶菌酶Cpl-1的全身应用可挽救患有致命性肺炎球菌肺炎的小鼠。
Crit Care Med. 2009 Feb;37(2):642-9. doi: 10.1097/CCM.0b013e31819586a6.
2
Antimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus.一种嵌合酶生素对金黄色葡萄球菌的抗菌活性。
J Biotechnol. 2009 Jan 1;139(1):118-23. doi: 10.1016/j.jbiotec.2008.09.003. Epub 2008 Sep 26.
3
Deaths from bacterial pneumonia during 1918-19 influenza pandemic.1918 - 1919年流感大流行期间因细菌性肺炎导致的死亡
Emerg Infect Dis. 2008 Aug;14(8):1193-9. doi: 10.3201/eid1408.071313.
4
Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis.用于实验性肺炎球菌性脑膜炎抗菌治疗的噬菌体裂解酶Cpl-1
J Infect Dis. 2008 Jun 1;197(11):1519-22. doi: 10.1086/587942.
5
What really happened during the 1918 influenza pandemic? The importance of bacterial secondary infections.1918年流感大流行期间究竟发生了什么?细菌继发感染的重要性。
J Infect Dis. 2007 Dec 1;196(11):1717-8; author reply 1718-9. doi: 10.1086/522355.
6
Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11.源自噬菌体phi MR11的克隆溶素对多重耐药金黄色葡萄球菌的高效清除
J Infect Dis. 2007 Oct 15;196(8):1237-47. doi: 10.1086/521305. Epub 2007 Sep 11.
7
LambdaSa1 and LambdaSa2 prophage lysins of Streptococcus agalactiae.无乳链球菌的LambdaSa1和LambdaSa2原噬菌体溶素。
Appl Environ Microbiol. 2007 Nov;73(22):7150-4. doi: 10.1128/AEM.01783-07. Epub 2007 Sep 28.
8
Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae.预防由肺炎链球菌定植引起的中耳炎的新策略。
PLoS Pathog. 2007 Mar;3(3):e28. doi: 10.1371/journal.ppat.0030028.
9
Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus.重组噬菌体phi11和phi12溶菌酶对金黄色葡萄球菌全细胞和生物膜的裂解活性。
Appl Environ Microbiol. 2007 Jan;73(1):347-52. doi: 10.1128/AEM.01616-06. Epub 2006 Nov 3.
10
Insights into the interaction between influenza virus and pneumococcus.流感病毒与肺炎球菌相互作用的见解。
Clin Microbiol Rev. 2006 Jul;19(3):571-82. doi: 10.1128/CMR.00058-05.